A country will receive 100 million doses of the “AstraZeneca” vaccine!

The Indian Institute “Serum”, which is the world’s largest vaccine manufacturer by volume, is working to increase its production of doses of an emerging “Corona” virus vaccine developed by British pharmaceutical giant “AstraZeneca”, with the aim of of providing around 100 million doses before December to start. In a campaign to vaccinate the population of India during the same month.

The Bloomberg news agency quoted Serum Institute executive director Adar Bunwala as saying that the institute may obtain a one-off license from the Indian government to begin the vaccination campaign next month if data from the third and final stage of clinical trials show that the “AstraZeneca” vaccine provides effective protection against the virus.

Bonwala added in an interview with ‘Bloomberg’ that India will receive 100 million doses of the vaccine, revealing that once the institute gets full approval, the distribution of the doses of the vaccine will begin equally between India and the Kovacs Foundation, which has the support of the World Health Organization to provide the vaccine to poor countries. Which guarantees that India receives vaccines for 20% of its population.

The “Serum” institute, located in the city of Pune in western India, and cooperating with 5 companies to develop vaccines to prevent the “Corona” virus, has managed to produce around 40 million doses of the “AstraZeneca” vaccine. for the past two months. The institute also aims to start soon the production of vaccine doses of the American company “Novafix”.

“We were a little concerned that this step could be very risky,” Bonualacna said, noting that “clinical trials of the vaccines” AstraZeneca “and” Novavex “are looking very good.

He noted that it will take until 2024 until the vaccine can be delivered to every country in the world, noting that a real decrease in the number of infections will take two years, due to affordability and manufacturing hurdles.

When asked about the vaccine from the American company “Pfizer”, the CEO of the “Serum” Institute said: “I don’t think that even 90% of the countries in the world can obtain it, because not everyone has the necessary cooling devices. to save the vaccine “, considering that simplicity is the solution to the deal. With any epidemic outbreak.

And last October, sources familiar with the matter said that New Delhi had earmarked about 500 billion rupees ($ 7.6 billion) to make “Crown” vaccines. However, Bonwala said that India would need around 800 billion rupees for this purpose and declined to comment further on this during the interview.